{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:37:00Z","timestamp":1792820220479,"version":"4.5.0"},"reference-count":79,"publisher":"Japan Atherosclerosis Society","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026]]},"DOI":"10.5551\/jat.66284","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:12:24Z","timestamp":1792534344000},"source":"Crossref","is-referenced-by-count":1,"title":["Remnant Clearance Capacity as a Determinant of Lipoprotein Oxidation: A Flux\u2013capacity Framework"],"prefix":"10.5551","author":[{"given":"Katsuyuki","family":"Nakajima","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Gunma University Graduate School of Medicine"},{"name":"Institute of Nutrition Science, Japan Nutrition University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Murakami","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine, Gunma University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Institute of Nutrition Science, Japan Nutrition University"},{"name":"Kichijoji Futaba Professional and Vocational College of Culinary Nutrition"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Steinberg DS, Parthasarathy TE, Carew J, Khoo C, and Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med., 1989; 320: 915-924","DOI":"10.1056\/NEJM198904063201407"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Witztum JL and Steinberg DS. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest., 1991; 88: 1785-1792","DOI":"10.1172\/JCI115499"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Witztum JL and Steinberg DS. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med, 2001; 11: 93-102","DOI":"10.1016\/S1050-1738(01)00111-6"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Holvoet P, Collen D. Oxidized lipoproteins in atherosclerosis and thrombosis. FASEB J, 1994; 8: 1279-1284","DOI":"10.1096\/fasebj.8.15.8001740"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med, 1996; 20: 707-727","DOI":"10.1016\/0891-5849(95)02173-6"},{"key":"6","unstructured":"6) Itabe H. Oxidized phospholipids as a new landmark in atherosclerosis. Prog Lipid Res, 2012; 51: 356-367"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Nakajima K, Nakano T and Tanaka A. The oxidative modification hypothesis of atherosclerosis: comparison of atherogenic effects of oxidized LDL and remnant lipoproteins. Clin. Chim. Acta., 2006; 367: 36-47","DOI":"10.1016\/j.cca.2005.12.013"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Kugiyama K, Doi H, Takazoe K, Kawano T, Soejima K, Mizuno H. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation, 1999; 99: 2858-2860","DOI":"10.1161\/01.CIR.99.22.2858"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PWF, Ordovas JM, Schaefer EJ. Remnant-like particle (RLP) cholesterol is an independent cardiovascular risk factor in women: results from the Framingham Heart Study. Atherosclerosis, 2001; 154: 229-236","DOI":"10.1016\/S0021-9150(00)00484-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Davies BSJ, Beigneux AP, Barnes RH II, Tu Y, Gin P, Weinstein MM, Nobumori C, Nyr\u00e9n R, Goldberg I, Olivecrona G, Bensadoun A, Young SG, Fong LG. GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab, 2010; 12: 42-52","DOI":"10.1016\/j.cmet.2010.04.016"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Fong LG, Young SG, Beigneux AP, Bensadoun A, Oberer M, and Jiang H. GPIHBP1 and plasma triglyceride metabolism. Trends Endocrinol. Metab., 2016; 27: 455-469","DOI":"10.1016\/j.tem.2016.04.013"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Goulbourne CN, Gin P, Tatar A, Nobumori C, Hoenger A, Jiang H, Grovenor CRM, Adeyo O, Esko JD, Goldberg IJ, Reue K, Tontonoz P, Bensadoun A, Beigneux AP, Young SG, Fong LG. The GPIHBP1\u2013LPL complex mediates margination of triglyceride-rich lipoproteins. Cell Metab, 2014; 19: 849-860","DOI":"10.1016\/j.cmet.2014.01.017"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Young SG, Fong LG, Beigneux AP, Allan CM, He C, Jiang H, Nakajima K, Meiyappan M, Birrane G, Ploug M. GPIHBP1 and lipoprotein lipase, partners in plasma triglyceride metabolism. Cell Metab, 2019; 30: 51-65","DOI":"10.1016\/j.cmet.2019.05.023"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Song W, Beigneux AP, Weston TA, Chen K, Yang Y, Nguyen LP, Guagliardo P, Jung H, Tran AP, Tu Y, Tran C, Birrane G, Miyashita K, Nakajima K, Murakami M, Tontonoz P, Jiang H, Ploug M, Fong LG, Young SG. Lipoprotein lipase detaches into the endothelial glycocalyx and mediates lipoprotein processing. Proc. Natl. Acad. Sci. U. S. A., 2023; 120: e2307732120","DOI":"10.1073\/pnas.2313825120"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Dallinga-Thie G M, Kroon J, Bor\u00e9n J and Chapman MJ. The metabolism of triglyceride-rich lipoproteins revisited. Atherosclerosis, 2010; 211: 1-8","DOI":"10.1016\/j.atherosclerosis.2009.12.027"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease. Circ. Res., 2016; 118: 547-563","DOI":"10.1161\/CIRCRESAHA.115.306249"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Schwartz EA, Reaven PD. Lipolysis of triglyceride-rich lipoproteins and vascular inflammation. Biochim. Biophys. Acta., 2012; 1821: 858-866","DOI":"10.1016\/j.bbalip.2011.09.021"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Botham KM, Wheeler-Jones CPD. Postprandial lipoproteins and vascular homeostasis. Prog Lipid Res., 2013; 52: 446-464","DOI":"10.1016\/j.plipres.2013.06.001"},{"key":"19","unstructured":"19) Packard CJ, Shepherd J. Lipoprotein metabolism and kinetics. Atherosclerosis, 1997; 130: 1-9"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Bj\u00f6rnson E, Packard CJ, Adiels M, Andersson L, Matikainen N, S\u00f6derlund S, Kahri J, Sihlbom C, Thorsell A, Zhou H, Taskinen MR, Bor\u00e9n J. Investigation of human apoB48 metabolism using a new, integrated non\u2013steady-state model of apoB48 and apoB100 kinetics. J Intern Med, 2019; 285: 562-580","DOI":"10.1111\/joim.12877"},{"key":"21","unstructured":"21) Hellerstein MK, Turner S. Measurement of apolipoprotein B synthesis and turnover using stable isotopes. J Lipid Res, 2014; 55: 237-248"},{"key":"22","unstructured":"22) Bor\u00e9n J, Chapman MJ. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease. Eur Heart J, 2020; 41: 99-109"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Taskinen MR, Bj\u00f6rnson E, Kahri J, S\u00f6derlund S, Matikainen N, Porthan K, Ainola M, Hakkarainen A, Lundbom N, Fermanelli V, Fuchs J, Thorsell A, Kronenberg F, Andersson L, Adiels M, Packard CJ, Bor\u00e9n J. Effects of PCSK9 inhibition with evolocumab on the postprandial metabolism of apolipoprotein B48\u2013 and B100\u2013containing lipoproteins. Arterioscler Thromb Vasc Biol, 2021; 41: 1199-1208","DOI":"10.1161\/ATVBAHA.120.315446"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Ginsberg HN, Packard CJ, Chapman MJ, Bor\u00e9n J, Aguilar-Salinas CA, Averna M, Ference BA, Gaudet D, Hegele RA, Kersten S, Lewis GF, Lichtenstein AH, Moulin P, Nordestgaard BG, Remaley AT, Staels B, Stroes ESG, Taskinen MR, Tokg\u00f6zo\u011flu LS, Tybj\u00e6rg-Hansen A, Stock JK, Catapano AL. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society. Eur Heart J, 2021; 42: 4791-4806","DOI":"10.1093\/eurheartj\/ehab551"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Taskinen MR, Bor\u00e9n J. New Insights Into the Pathophysiology of Dyslipidemia in Type 2 Diabetes. Arterioscler Thromb Vasc Biol, 2015; 35: 151-160","DOI":"10.1016\/j.atherosclerosis.2015.01.039"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Beigneux AP, Davies BSJ, Gin P, Weinstein MM, Farber E, Qiao X, Peale F, Bunting S, Walzem RL, Wong JS, Blaner WS, Ding ZM, Melford K, Wongsiriroj N, Shu X, de Sauvage F, Ryan RO, Fong LG, Bensadoun A, Young SG. GPIHBP1, a glycosylphosphatidylinositol-anchored protein of capillary endothelial cells, plays a critical role in the lipolytic processing of chylomicrons. Cell Metabolism, 2007; 5: 279-291","DOI":"10.1016\/j.cmet.2007.02.002"},{"key":"27","unstructured":"27) Ploug M, Beigneux AP, Young SG. Structure and function of GPIHBP1 Current Opinion in Lipidology. 2021; 32: 122-130"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med, 2002; 80: 753-769","DOI":"10.1007\/s00109-002-0384-9"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Tall AR, Rader DJ. The Trials and Tribulations of CETP Inhibitors. Circ Res, 2018; 122: 106-112","DOI":"10.1161\/CIRCRESAHA.117.311978"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Santamarina-Fojo S, Haudenschild C, Amar M. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol, 1998; 9: 211-219","DOI":"10.1097\/00041433-199806000-00005"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res, 1996; 37: 693-707","DOI":"10.1016\/S0022-2275(20)37569-6"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Franssen R, Young SG, Peelman F, Hertecant J, Sierts JA, Schimmel AWM, Bensadoun A, Kastelein JJP, Fong LG, Dallinga-Thie GM, Beigneux AP. Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects. Circ Cardiovasc Genet, 2010; 3: 169-178","DOI":"10.1161\/CIRCGENETICS.109.908905"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Beigneux AP, Miyashita K, Ploug M, Blom DJ, Ai M, Linton MF, Khovidhu nkit W, Dufour R, Garg A, McMahon MA, Pullinger CR, Sandoval NP, Hu X, Allan CM, Larsson M, Machida T, Murakami M, Reue K, Tontonoz P, Goldberg IJ, Moulin P, Charri\u00e8re S, Fong LG, Nakajima K, Young SG. Autoantibodies against GPIHBP1 as a cause of hypertriglyceridemia. N Engl J Med, 2017; 376: 1647-165","DOI":"10.1056\/NEJMoa1611930"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Wolska A, Dunbar RL, Freeman LA, Ueda M, Amar MJ, Sviridov DO, Remaley AT. Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism. Atherosclerosis, 2017; 267: 49-60","DOI":"10.1016\/j.atherosclerosis.2017.10.025"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Forte TM, Shu X, Ryan RO. The ins (cell) and outs (plasma) of A-V. J Lipid Res, 2009; 50(Suppl): S150-S155","DOI":"10.1194\/jlr.R800050-JLR200"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Bor\u00e9n J, Packard CJ, Taskinen MR. The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans. Front Endocrinol (Lausanne), 2020; 11: 474","DOI":"10.3389\/fendo.2020.00474"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Sylvers-Davie KL, Davies BSJ. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8. Am J Physiol Endocrinol Metab, 2021; 321: E493-E508","DOI":"10.1152\/ajpendo.00195.2021"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res, 1999; 40: 1-16","DOI":"10.1016\/S0022-2275(20)33334-4"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Stanford KI, Bishop JR, Foley EM, Gonzales JC, Niesman IR, Witztum JL, Esko JD. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest, 2009; 119: 3236-3245","DOI":"10.1172\/JCI38251"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev, 2004; 84: 1381-1478","DOI":"10.1152\/physrev.00047.2003"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atherosclerosis, 2002; 161: 1-16","DOI":"10.1016\/S1567-5688(01)80008-8"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Kugiyama K, Doi H, Motoyama T, Soejima H, Misumi K, Matsumura T, Sugiyama S, Nakano T, Nakajima K, Yasue H. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation, 1998; 97: 2519-2526","DOI":"10.1161\/01.CIR.97.25.2519"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Kugiyama K, Motoyama T, Doi H, Kawano H, Hirai N, Soejima H, Miyao Y, Takazoe K, Moriyama Y, Mizuno Y, Tsunoda R, Ogawa H, Sakamoto T, Sugiyama S, Yasue H. Improvement of endothelial vasomotor dysfunction by treatment with alpha-tocopherol in patients with high remnant lipoproteins levels. J Am Coll Cardiol, 1999; 33: 1512-1518","DOI":"10.1016\/S0735-1097(99)00057-1"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Doi H, Kugiyama K, Ohgushi M, Sugiyama S, Matsumura T, Ohta Y, Nakano T, Nakajima K, Yasue H. Remnants of chylomicron and very low density lipoprotein impair endothelium-dependent vasorelaxation. Atherosclerosis, 1998; 137: 341-349","DOI":"10.1016\/S0021-9150(97)00291-8"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Shin HK, Kim YK, Kim KY, Lee JH, Hong KW. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation, 2004; 109: 1022-1028","DOI":"10.1161\/01.CIR.0000117403.64398.53"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol, 1995; 15: 551-561","DOI":"10.1161\/01.ATV.15.5.551"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem, 1997; 272: 20963-20966","DOI":"10.1074\/jbc.272.34.20963"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Goldberg IJ, Eckel RH, McPherson R. Triglyceride-rich lipoproteins and cardiovascular disease: still a hypothesis? Arterioscler Thromb Vasc Biol, 2011; 31: 1716-1725","DOI":"10.1161\/ATVBAHA.111.226100"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Fruchart JC, Sacks FM, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner \u017d, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol, 2008; 102(Suppl): 1K-34K","DOI":"10.1016\/j.amjcard.2008.10.002"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokg\u00f6zo\u011flu L, Wiklund O; ESC Scientific Document Group. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020; 41: 111-188","DOI":"10.15829\/1560-4071-2020-3826"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano AL, Ference BA. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol, 2019; 4: 1287-1295","DOI":"10.1001\/jamacardio.2019.3780"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Libby P. The changing landscape of atherosclerosis. Nature, 2021; 592: 524-533","DOI":"10.1038\/s41586-021-03392-8"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med, 2017; 377: 1119-1131","DOI":"10.1056\/NEJMoa1707914"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream to Identify Novel Targets for Atheroprotection. Circ Res, 2016; 118: 145-156","DOI":"10.1161\/CIRCRESAHA.115.306656"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol, 2017; 69: 692-711","DOI":"10.1016\/j.jacc.2016.11.042"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky ML, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokg\u00f6zo\u011flu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J, 2022; 43: 3925-3946","DOI":"10.1093\/eurheartj\/ehac361"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Binder CJ, Papac-Milicevic N, Witztum JL. Innate sensing of oxidation-specific epitopes in health and disease. Nat Rev Immunol, 2016; 16: 485-497","DOI":"10.1038\/nri.2016.63"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Varbo A, Benn M, Tybj\u00e6rg-Hansen A, J\u00f8rgensen AB, Frikke-Schmidt R, and Nordestgaard BG. Remnant cholesterol as a causal risk factor. J. Am. Coll. Cardiol., 2013; 61: 427-436","DOI":"10.1016\/j.jacc.2012.08.1026"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet, 2014; 384: 626-635","DOI":"10.1016\/S0140-6736(14)61177-6"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Tabas I, Williams KJ, Bor\u00e9n J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation, 2007; 116: 1832-1844","DOI":"10.1161\/CIRCULATIONAHA.106.676890"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Verg\u00e8s B. Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia, 2015; 58: 886-899","DOI":"10.1007\/s00125-015-3525-8"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, Melquist S, Zhou R, Mushin M, Leeper NJ, Hellawell J, Gaudet D. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med, 2024; 391: 899-912","DOI":"10.1056\/NEJMoa2404143"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Dewey FE, Gusarova V, Dunbar RL, O\u2019Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV, Bruse S, Dansky HM, Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stahl N, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH, Lee IT, Liang KW, Guo X, Rotter JI, Chen YDI, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Wulff AB, Nordestgaard BG, Tybj\u00e6rg-Hansen A, van den Hoek AM, Princen HMG, Ledbetter DH, Carey DJ, Overton JD, Reid JG, Sasiela WJ, Banerjee P, Shuldiner AR, Borecki IB, Teslovich TM, Yancopoulos GD, Mellis SJ, Gromada J, Baras A. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med, 2017; 377: 211-221","DOI":"10.1056\/NEJMoa1612790"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Patsch JR, Miesenb\u00f6ck G, Hopferwieser T, M\u00fchlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb, 1992; 12: 1336-1345","DOI":"10.1161\/01.ATV.12.11.1336"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) O\u2019Keefe JH, Bell DSH. Postprandial hyperglycemia\/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol, 2007; 100: 899-904","DOI":"10.1016\/j.amjcard.2007.03.107"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Masuda D, Yamashita S. Postprandial Hyperlipidemia and Remnant Lipoproteins. J Atheroscler Thromb, 2017; 24: 95-109","DOI":"10.5551\/jat.RV16003"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67) Cohn JS, Marcoux C, Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol, 1999; 19: 2474-2486","DOI":"10.1161\/01.ATV.19.10.2474"},{"key":"68","unstructured":"68) Spickett CM, Pitt AR. Oxidative lipidomics coming of age: advances in analysis of oxidized phospholipids and lipid peroxidation products by mass spectrometry. Free Radic Biol Med, 2015; 88: 11-19"},{"key":"69","unstructured":"69) Davidson WS, Shah AS. High-density lipoprotein proteomics and its potential clinical applications. J Lipid Res, 2015; 56: 250-257"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70) Quehenberger O, Dennis EA. The Human Plasma Lipidome N Engl J Med, 2011; 365: 1812-1823","DOI":"10.1056\/NEJMra1104901"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71) Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E, Havel RJ. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti-apoB-100 and anti-apoA-I immunoaffinity mixed gel. Clin Chim Acta, 1993; 223: 53-71","DOI":"10.1016\/0009-8981(93)90062-9"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72) Chapman MJ, Packard CJ, Bj\u00f6rnson E, Ginsberg HN, Bor\u00e9n J. Triglyceride-rich lipoproteins, remnants and atherosclerotic cardiovascular disease: What we know and what we need to know. Atherosclerosis, 2025; 410: 120529","DOI":"10.1016\/j.atherosclerosis.2025.120529"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73) Nagasawa T, Nakajima K, Shirakawa T, Miyashita K, Fukamachi I, Tanaka A, Wang J, McIntyre AD, Hegele RA, Nakajima K, Tsunekawa K, Murakami M. A novel dual-epitope ELISA reveals heterogeneity of circulating lipoprotein lipase: distinguishing intact LPL from total LPL. Clin Chim Acta, 2026, in press","DOI":"10.1016\/j.cca.2026.122896"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74) Kolovou GD, Mikhailidis DP, Nordestgaard BG, Bilianou H, Panotopoulos G. Definition of postprandial lipaemia. Curr Vasc Pharmacol, 2011; 9: 292-301","DOI":"10.2174\/157016111795495611"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75) Funada J, Sekiya M, Hamada M, Hiwada K. Postprandial Elevation of Remnant Lipoprotein Leads to Endothelial Dysfunction. Circ J, 2002; 66: 127-132","DOI":"10.1253\/circj.66.127"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76) Maggi FM, Raselli S, Grigore L, Redaelli L, Fantappi\u00e8 S, Catapano AL. Lipoprotein Remnants and Endothelial Dysfunction in the Postprandial Phase. J Clin Endocrinol Metab, 2004; 89: 2946-2950","DOI":"10.1210\/jc.2003-031977"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77) Okazaki H, Gotoda T, Ogura M, Ishibashi S, Inagaki K, Daida H, Hayashi T, Hori M, Masuda D, Matsuki K, Yokoyama S, Harada-Shiba M. Current Diagnosis and Management of Primary Chylomicronemia. J Atheroscler Thromb, 2021; 28: 883-904","DOI":"10.5551\/jat.RV17054"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78) Paquette M, Bernard S, Hegele RA, Baass A. Chylomicronemia: Differences between familial chylomicronemia syndrome and multifactorial chylomicronemia. Atherosclerosis, 2019; 283: 137-142","DOI":"10.1016\/j.atherosclerosis.2018.12.019"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79) Paquette M, Bernard S. The Evolving Story of Multifactorial Chylomicronemia Syndrome. Front Cardiovasc Med, 2022; 9: 886266","DOI":"10.3389\/fcvm.2022.886266"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/advpub\/0\/advpub_66284\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:47:05Z","timestamp":1792817225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/advpub\/0\/advpub_66284\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":79,"URL":"https:\/\/doi.org\/10.5551\/jat.66284","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"66284"}}